Omada Health reported revenue of $87.83M and net income of $5.29M for the quarter ended Jun 2026, up 43.1% year over year. This income statement covers 9 quarters of results from Jun 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||
| Revenue | 41.21M | 45.52M | 47.98M | 54.96M | 61.37M | 68.03M | 75.85M | 78.05M | 87.83M |
| Cost of RevenueCost of Rev | 16.38M | 16.95M | 15.85M | 23.06M | 21.07M | 22.96M | 22.18M | 29.36M | 24.05M |
| Gross Profit | 24.83M | 28.56M | 32.13M | 31.90M | 40.31M | 45.07M | 53.66M | 48.69M | 63.79M |
| Operating items | |||||||||
| Research & DevelopmentR&D | 15.19M | 17.58M | 18.09M | 20.17M | 22.32M | 22.94M | 24.61M | 26.79M | 29.89M |
| Selling, General & AdministrativeSG&A | 10.69M | 10.66M | 11.95M | 11.32M | 12.31M | 14.34M | 14.22M | 13.99M | 15.72M |
| Other Operating ExpensesOther Opex | 8.99M | 8.85M | 9.19M | 8.81M | 10.02M | 10.30M | 11.55M | 12.70M | 14.62M |
| Operating ExpensesOpex | 34.87M | 37.09M | 39.23M | 40.30M | 44.65M | 47.58M | 50.38M | 53.47M | 60.24M |
| Operating IncomeOp. Inc | -10.04M | -8.52M | -7.10M | -8.40M | -4.34M | -2.51M | 3.28M | -4.78M | 3.55M |
| EBIT | -10.04M | -8.52M | -7.10M | -8.40M | -4.34M | -2.51M | 3.28M | -4.78M | 3.55M |
| Non-operating items | |||||||||
| Non Operating Interest Expenses | 1.13M | 1.15M | 1.10M | 1.07M | 1.09M | 0.35M | 0.01M | 0.02M | 0.01M |
| Interest & Investment IncomeInt & Inv Inc | 0.09M | 0.02M | 0.17M | 0.54M | 0.86M | 2.01M | 1.89M | 1.83M | 1.76M |
| Other Non Operating IncomeOther Non Op Inc. | -2.11M | ||||||||
| Non Operating IncomeNon Op. Inc. | -0.66M | -0.70M | -1.15M | -1.05M | -0.97M | -0.67M | 1.88M | 1.81M | 1.75M |
| Net income details | |||||||||
| EBT | -10.69M | -9.23M | -8.25M | -9.45M | -5.31M | -3.18M | 5.16M | -2.97M | 5.29M |
| Profit After TaxPAT | -10.69M | -9.23M | -8.25M | -9.45M | -5.31M | -3.18M | 5.16M | -2.97M | 5.29M |
| Income from Continuing OperationsIncome (Continuing) | -10.69M | -9.23M | -8.25M | -9.45M | -5.31M | -3.18M | 5.16M | -2.97M | 5.29M |
| Consolidated Net IncomeConsol Net Inc. | -10.69M | -9.23M | -8.25M | -9.45M | -5.31M | -3.18M | 5.16M | -2.97M | 5.29M |
| Income towards Parent CompanyParent Net Inc | -10.69M | -9.23M | -8.25M | -9.45M | -5.31M | -3.18M | 5.16M | -2.97M | 5.29M |
| Net Income towards Common StockholdersNet Income | -10.69M | -9.23M | -8.25M | -9.45M | -5.31M | -3.18M | 5.16M | -2.97M | 5.29M |
| Additional items | |||||||||
| EPS (Basic) | -1.40 | -1.18 | -1.07 | -1.15 | -0.24 | -0.06 | 0.14 | -0.05 | 0.09 |
| EPS (Diluted) | -1.40 | -1.18 | -1.07 | -1.15 | -0.24 | -0.06 | 0.14 | -0.05 | 0.08 |
| Shares Outstanding | 7.65M | 7.79M | 7.72M | 8.24M | 21.97M | 57.66M | 36.64M | 58.92M | 59.69M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 7.65M | 7.79M | 7.72M | 8.24M | 21.97M | 57.66M | 36.64M | 58.92M | 63.95M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 7.72M | 7.85M | 8.16M | 8.36M | 21.97M | 57.89M | 36.64M | 59.24M | 60.61M |
| EBITDA | -10.04M | -8.52M | -7.10M | -8.40M | -4.34M | -2.51M | 3.28M | -4.78M | 3.55M |
| Interest ExpensesInt Expense | 1.13M | 1.15M | 1.10M | 1.07M | 1.09M | 0.35M | 0.01M | 0.02M | 0.01M |